Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
Menée à partir de données portant sur 318 patients atteints d'une tumeur fibreuse solitaire extraméningée de stade localisé, cette étude évalue la performance d'un système de score, incluant le sexe, le nombre de mitoses et la présence d'une nécrose, pour prédire le risque de récidive précoce ou tardive
Background : Current risk models in solitary fibrous tumour (SFT) were developed using cohorts with short follow-up and cannot reliably identify low-risk patients. We recently developed a novel risk model (G-score) to account for both early and late recurrences. Here, we aimed to validate the G-score in a large international cohort with long-term follow-up.
Methods : Data were collected from nine sarcoma referral centres worldwide. Recurrence-free interval (RFi) was the primary endpoint.
Results : The cohort comprised 318 patients with localised extrameningeal SFTs. Disease recurrence occurred in 96 patients (33%). The estimated 5-year RFi rate was 72%, and the 10-year RFi rate was 52%. G-score precisely predicted recurrence risk with estimated 10-year RFi rate of 84% in low risk, 54% in intermediate risk and 36% in high risk (p < 0.001; C-index 0.691). The mDemicco (p < 0.001; C-index 0.749) and SalasOS (p < 0.001; C-index 0.674) models also predicted RFi but identified low-risk patients less accurate with 10-year RFi rates of 72% and 70%, respectively.
Conclusions : G-score is a highly significant predictor of early and late recurrence in SFT and is superior to other models to predict patients at low risk of relapse. A less intensive follow-up schedule could be considered for patients at low recurrence risk according to G-score.
British Journal of Cancer , résumé, 2022